Full Breakdown
FDA Grants First Gene Therapy Approval for Sanfilippo Syndrome Type A
By Drooid · · How we work
Core Approval Details
The U.S. Food and Drug Administration granted full approval of Fayuvi (rebisufligene etisparvovec-hopf) for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) who retain neurodevelopmental function. The therapy is administered as a single intravenous infusion at a network of Qualified Treatment Centers. Ultragenyx has set a U.S. list price of $3.95 million; Pharmaphorum reports a price of $3.9 million, reflecting a discrepancy among sources. Commercial shipments are expected within 30–60 days of approval.
Clinical Evidence
The pivotal Transpher A trial enrolled 17 treated children (modified intention-to-treat) and compared them with 27 patients from an external natural-history cohort. Treated participants showed a 23.5-point higher Bayley-III Cognitive raw score (p < 0.0001). Long-term follow-up, extending to nearly eight years, demonstrated durable reductions in cerebrospinal-fluid heparan sulfate, the substrate that accumulates in MPS IIIA. Across the study, children maintained or improved cognitive function relative to untreated controls.
Patient Impact & Disease Burden
MPS IIIA results from a deficiency of the sulfamidase (SGSH) enzyme, causing heparan sulfate buildup and progressive neurodegeneration. The condition typically limits life expectancy to about 15 years. Ultragenyx estimates 3,000–5,000 patients in commercially accessible geographies. The company argues that lifetime care costs for a child with MPS IIIA can exceed $8 million, a figure it cites to contextualize the therapy’s price.
Economic Outlook
- Jefferies projects peak worldwide sales of ? $250 million.
- J.P. Morgan analysts estimate a sales range of $200–$250 million.
- The approval also awarded Ultragenyx a Priority Review Voucher (PRV). William Blair analysts note that PRVs trade at roughly $200 million and anticipate a sale after June 30 (scheduled).
Official Statements & Responses
- “We recognise the profound urgency of making this therapy available to families, and our focus now is on supporting timely access in the US as we work closely with treatment centres and payers to support families on the gene therapy treatment journey,” — the company.
- Ultragenyx highlighted its existing manufacturing infrastructure, asserting it can drive production costs toward “biologics-like levels.”
On-the-Ground Reports
A family whose child received Fayuvi reported that the patient has never experienced a seizure, does not require a feeding tube or wheelchair, attends school, and participates in swimming—outcomes the family says far exceed typical disease trajectories.
Conflicting Reports & Gaps
- Price discrepancy: Sources list the list price as $3.95 million (BioSpace, Islandpacket) and $3.9 million. No clarification is provided on which figure is final.
- Payer coverage: While the company cites an $8 million lifetime care cost, details on insurance reimbursement or government assistance remain undisclosed.
What’s Next
- Ultragenyx expects to ship Fayuvi to Qualified Treatment Centers within 30–60 days.
- The company plans to sell its PRV after June 30 (scheduled).
- The FDA’s resubmission was accepted with a PDUFA target date of September 19, 2026 (scheduled).
Verbatim Quotes
- “We recognise the profound urgency of making this therapy available to families, and our focus now is on supporting timely access in the US as we work closely with treatment centres and payers to support families on the gene therapy treatment journey,” — the company